Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11339385 | 0.82 | ENPEP (0.32) | TSHRLMNA | |
| SCHEMBL4886842 | 0.81 | CA2 (0.39) | CA1CA2TSHRLMNAHSD17B10 | |
| SCHEMBL11333891 | 0.80 | CA1 (0.37) | CA1CA2KIF11TSHRLMNA | |
| SCHEMBL18770575 | 0.78 | CA1 (0.35) | CA1CA2KIF11 | |
| SCHEMBL19178067 | 0.78 | ECE1 (0.32) | — | |
| SCHEMBL28639368 | 0.78 | CA2 (0.50) | CA1CA2 | |
| SCHEMBL1572815 | 0.77 | TSHR (0.36) | CA2KIF11TSHRHSD17B10 | |
| SCHEMBL22689595 | 0.77 | CA2 (0.38) | CA1CA2TSHRLMNAHSD17B10 | |
| SCHEMBL8598405 | 0.77 | ALOX15 (0.36) | CA1CA2KIF11TSHRLMNA | |
| SCHEMBL5369984 | 0.77 | TSHR (0.36) | CA2KIF11TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7235258-B1 | Sustained-release formulations for treating CNS-mediated disorders | NPS PHARMACEUTICALS, INC. (US) | 2007-06-26 | — | — | US | claimed |
| EP-1576962-A1 | Composition comprising isovaleramide and ibuprofen | NPS PHARMACEUTICALS, INC. (US) | 2005-09-21 | — | — | EP | claimed |
| US-20040072900-A1 | Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound | NPS PHARMACEUTICALS | 2004-04-15 | — | — | US | claimed |
| JP-2002538106-A | — | — | 2002-11-12 | — | — | JP | claimed |
| EP-1225888-A2 | SUSTAINED-RELEASE FORMULATIONS FOR TREATING CNS-MEDIATED DISORDERS | NPS PHARMACEUTICALS, INC. (US) | 2002-07-31 | — | — | EP | claimed |
| US-6383527-B1 | FOR TREATMENT OF ACUTE MUSCULAR ACHES, STRAINS, AND SPRAINS WHICH OCCUR FROM A LOCALIZED, EXTERNAL INSULT TO A PARTICULAR MUSCLE OR MUSCLE GROUP | NPS PHARMACEUTICALS, INC. | 2002-05-07 | — | — | US | claimed |
| EP-1176953-A2 | TREATMENT OF A VARIETY OF PATHOLOGICAL CONDITIONS, INCLUDING SPASTICITY AND CONVULSIONS, BY EFFECTING MODULATION OF CNS ACTIVITY WITH ISOVALERAMIDE, ISOVALERIC ACID, OR A RELATED COMPOUND | NPS PHARMACEUTICALS, INC. (US) | 2002-02-06 | — | — | EP | claimed |
| WO-2001028516-A2 | SUSTAINED-RELEASE FORMULATIONS FOR TREATING CNS-MEDIATED DISORDERS | NPS PHARMACEUTICALS, INC. (US) | 2001-04-26 | — | — | WO | claimed |
| EP-1059930-A1 | COMPOSITIONS COMPRISING VALERIAN EXTRACTS, ISOVALERIC ACID OR DERIVATIVES THEREOF WITH A NSAID | NPS PHARMACEUTICALS, INC. (US) | 2000-12-20 | — | — | EP | claimed |
| WO-2000051586-A2 | TREATING A VARIETY OF PATHOLOGICAL CONDITIONS, INCLUDING SPASTICITY AND CONVULSIONS, BY EFFECTING MODULATION OF CNS ACTIVITY WITH ISOVALERAMIDE, ISOVALERIC ACID, OR A RELATED COMPOUND | NPS PHARMACEUTICALS, INC. (US) | 2000-09-08 | — | — | WO | claimed |
| WO-1999044623-A1 | COMPOSITIONS COMPRISING VALERIAN EXTRACTS, ISOVALERIC ACID OR DERIVATIVES THEREOF WITH A NSAID | NPS PHARMACEUTICALS, INC. (US) | 1999-09-10 | — | — | WO | claimed |
| US-20230024302-A1 | 2,3,5-TRISUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS | ARCUS BIOSCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
| CN-106349156-B | It can be used as the pyridine -2- amides of CB2 agonist | 霍夫曼-拉罗奇有限公司 | 2018-12-11 | — | — | CN | disclosed |
| CN-106349156-A | Pyridine-2-amides capable of being used as CB2 agonist | 霍夫曼-拉罗奇有限公司 | 2017-01-25 | — | — | CN | disclosed |
| CN-103608332-B | Pyridine-2-amides useful as CB2 agonists | 霍夫曼-拉罗奇有限公司 | 2016-09-28 | — | — | CN | disclosed |
| US-6383527-B1 | FOR TREATMENT OF ACUTE MUSCULAR ACHES, STRAINS, AND SPRAINS WHICH OCCUR FROM A LOCALIZED, EXTERNAL INSULT TO A PARTICULAR MUSCLE OR MUSCLE GROUP | NPS PHARMACEUTICALS, INC. | 2002-05-07 | — | — | US | disclosed |
| WO-2001028516-A2 | SUSTAINED-RELEASE FORMULATIONS FOR TREATING CNS-MEDIATED DISORDERS | NPS PHARMACEUTICALS, INC. (US) | 2001-04-26 | — | — | WO | disclosed |
| EP-1059930-A1 | COMPOSITIONS COMPRISING VALERIAN EXTRACTS, ISOVALERIC ACID OR DERIVATIVES THEREOF WITH A NSAID | NPS PHARMACEUTICALS, INC. (US) | 2000-12-20 | — | — | EP | disclosed |
| WO-1999044623-A1 | COMPOSITIONS COMPRISING VALERIAN EXTRACTS, ISOVALERIC ACID OR DERIVATIVES THEREOF WITH A NSAID | NPS PHARMACEUTICALS, INC. (US) | 1999-09-10 | — | — | WO | disclosed |
| EP-0677038-B1 | METHOD FOR AMIDE PREPARATION | EXXON CHEMICAL PATENTS INC (US) | 1998-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072900-A1 | Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound | GABRG3, NLN, GABRA4 | CA1 216/4885CA2 559/4885KIF11 799/4885 |
| US-20230024302-A1 | 2,3,5-TRISUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS | PIK3CA, PIK3CG, PIK3CD | CA1 4788/4885CA2 4520/4885KIF11 3391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.